全文获取类型
收费全文 | 444557篇 |
免费 | 35141篇 |
国内免费 | 15091篇 |
专业分类
耳鼻咽喉 | 3534篇 |
儿科学 | 7032篇 |
妇产科学 | 6377篇 |
基础医学 | 60911篇 |
口腔科学 | 8284篇 |
临床医学 | 34496篇 |
内科学 | 70140篇 |
皮肤病学 | 5825篇 |
神经病学 | 31894篇 |
特种医学 | 11940篇 |
外国民族医学 | 80篇 |
外科学 | 34767篇 |
综合类 | 63404篇 |
现状与发展 | 51篇 |
一般理论 | 14篇 |
预防医学 | 31816篇 |
眼科学 | 6636篇 |
药学 | 58946篇 |
121篇 | |
中国医学 | 22744篇 |
肿瘤学 | 35777篇 |
出版年
2024年 | 1125篇 |
2023年 | 7065篇 |
2022年 | 16137篇 |
2021年 | 20364篇 |
2020年 | 16043篇 |
2019年 | 14491篇 |
2018年 | 14386篇 |
2017年 | 15350篇 |
2016年 | 15483篇 |
2015年 | 16108篇 |
2014年 | 22913篇 |
2013年 | 28391篇 |
2012年 | 24437篇 |
2011年 | 28417篇 |
2010年 | 21648篇 |
2009年 | 21783篇 |
2008年 | 23019篇 |
2007年 | 23027篇 |
2006年 | 21032篇 |
2005年 | 18911篇 |
2004年 | 16044篇 |
2003年 | 14185篇 |
2002年 | 11398篇 |
2001年 | 9858篇 |
2000年 | 8307篇 |
1999年 | 7212篇 |
1998年 | 6115篇 |
1997年 | 5823篇 |
1996年 | 5326篇 |
1995年 | 4667篇 |
1994年 | 4288篇 |
1993年 | 3504篇 |
1992年 | 3120篇 |
1991年 | 2850篇 |
1990年 | 2447篇 |
1989年 | 1999篇 |
1988年 | 1850篇 |
1987年 | 1592篇 |
1986年 | 1445篇 |
1985年 | 2184篇 |
1984年 | 1879篇 |
1983年 | 1353篇 |
1982年 | 1443篇 |
1981年 | 1163篇 |
1980年 | 1063篇 |
1979年 | 821篇 |
1978年 | 537篇 |
1977年 | 455篇 |
1976年 | 431篇 |
1975年 | 306篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
《Clinical neurophysiology》2020,131(1):213-224
ObjectiveSystematically review the abnormalities in event related potential (ERP) recorded in Rett Syndrome (RTT) patients and animals in search of translational biomarkers of deficits related to the particular neurophysiological processes of known genetic origin (MECP2 mutations).MethodsPubmed, ISI Web of Knowledge and BIORXIV were searched for the relevant articles according to PRISMA standards.ResultsERP components are generally delayed across all sensory modalities both in RTT patients and its animal model, while findings on ERPs amplitude strongly depend on stimulus properties and presentation rate. Studies on RTT animal models uncovered the abnormalities in the excitatory and inhibitory transmission as critical mechanisms underlying the ERPs changes, but showed that even similar ERP alterations in auditory and visual domains have a diverse neural basis. A range of novel approaches has been developed in animal studies bringing along the meaningful neurophysiological interpretation of ERP measures in RTT patients.ConclusionsWhile there is a clear evidence for sensory ERPs abnormalities in RTT, to further advance the field there is a need in a large-scale ERP studies with the functionally-relevant experimental paradigms.SignificanceThe review provides insights into domain-specific neural basis of the ERP abnormalities and promotes clinical application of the ERP measures as the non-invasive functional biomarkers of RTT pathophysiology. 相似文献
62.
目的探讨补骨脂素抗增生性瘢痕的作用机制。方法体外培养成纤维细胞,按随机数字表法分为正常组(培养正常成纤维细胞)、瘢痕组(培养增生性瘢痕成纤维细胞)、TGF-β1组(10 ng/ml TGF-β1处理增生性瘢痕成纤维细胞5 min^12 h)、Smurf2 RNA干扰组[Smad泛素化调节因子2(Smad ubiquitin regulatory factor2,Smurf2)siRNA转染增生性瘢痕成纤维细胞72 h]、补骨脂素组(10μmol/L补骨脂素处理增生性瘢痕成纤维细胞继续培养72 h)、补骨脂素+TGF-β1组(增生性瘢痕成纤维细胞加入补骨脂素培养72 h后加入TGF-β1培养6 h)。采用Western blot法检测Smurf2、α-平滑肌肌动蛋白(α-actin SMA,α-SMA)蛋白表达;RT-PCR法检测Ⅰ型胶原蛋白mRNA表达;ELISA法检测TGF-β1蛋白分泌。结果与正常组比较,瘢痕组Smurf2蛋白[(0.83±0.08)比(0.38±0.07)]表达增加(P<0.05);与瘢痕组比较,Smurf2 RNA干扰组TGF-β1[(2.2±0.18)比(4.2±0.47)]表达降低(P<0.05);TGF-β1组Smurf2[(0.71±0.06)比(0.42±0.04)]、α-SMA[(1.42±0.12)比(0.91±0.09)]蛋白表达增加(P<0.05),Ⅰ型胶原蛋白mRNA[(0.72±0.09)比(0.41±0.07)]表达增加(P<0.05);补骨脂素组Smurf2[(0.05±0.01)比(0.42±0.04)]、α-SMA[(0.71±0.07)比(0.91±0.09)]蛋白表达降低(P<0.05),Ⅰ型胶原蛋白mRNA表达[(0.12±0.04)比(0.41±0.07)]降低(P<0.05)。结论补骨脂素可能通过TGF-β1/Smurf2信号通路抑制α-SMA蛋白表达,从而降低Ⅰ型胶原蛋白表达,起到抑制瘢痕形成的作用。 相似文献
63.
64.
Wan-Jie Gu 《Journal of thoracic disease》2015,7(11):1885-1886
It is well known that a meta-analysis of randomized controlled trials aims to increase the power and precision of the estimated intervention effects. However, when a meta-analysis includes a limited number of patients and a small number of events, overestimation of intervention effect estimates may occur and could cause spurious results. Although many biases can cause the overestimation, random error may be the most common cause. Trial sequential analysis (TSA) can explore the independent effect of random error on intervention effect estimates in meta-analyses and protect meta-analyses against overestimation due to random error. 相似文献
65.
《Journal of Clinical Orthopaedics and Trauma》2019,10(2):380-386
Additive manufacturing is a rapidly emerging technology which is being successfully implemented in the various field of medicine as well as in orthopaedics, where it has applications in reducing cartilage defects and treatments of bones. The technology helps through systematic collection of information about the shape of the "defects" and precise fabrication of complex 3D constructs such as cartilage, heart valve, trachea, myocardial bone tissue and blood vessels. In this paper, a large number of the relevant research papers on the additive manufacturing and its application in medical specifically orthopaedics are identified through Scopus had been studied using Bibliometric analysis and application analysis is undertaken. The bibliometric analysis shows that there is an increasing trend in the research reports on additive manufacturing applications in the field of orthopaedics. Discussions are on using technological advancement like scanning techniques and various challenges of the orthopaedic being met by additive manufacturing technology. For patient-specific orthopaedic applications, these techniques incorporate clinical practice and use for effective planning. 3D printed models printed by this technology are accepted for orthopaedic surgery such as revision of lumbar discectomy, pelvic surgery and large scapular osteochondroma. The applications of additive manufacturing in orthopaedics will experience a rapid translation in future. An orthopaedic surgeon can convert need/idea into a reality by using computer-aided design (CAD) software, analysis software to facilitate the manufacturing. Thus, AM provides a comprehensive opportunity to manufacture orthopaedic implantable medical devices. 相似文献
66.
67.
OBJECTIVES: To assess the effectiveness and safety of additional bedtime H2‐receptor antagonists (H2RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H2RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H2RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H2RAs in suppressing NAB. 相似文献
68.
《Journal of labelled compounds & radiopharmaceuticals》2006,49(4):339-343
Condensation of thiourea 1 with diethyl malonate 2 in the presence of sodium methoxide furnished 4,6‐dihydroxy‐2‐mercaptopyrimidine 3 . Compound 3 on methylation with diazomethane followed by oxidation with H5IO6/CrO3 in ethyl acetate gave 4,6‐dimethoxy‐2‐methylsulphonylpyrimidine 5 . Compound 5 on condensation with 2‐mercapto‐6‐chlorobenzoic acid in the presence of a phase transfer catalyst, tetrabutylammonium bromide and sodium carbonate gave the title compound – pyrithiobac‐sodium 6 with an overall yield of > 35% starting from thiourea. Following the above standardized procedure, using [14C]‐thiourea in lieu of thiourea, 14C labelled product 6 , was synthesized with an overall radiochemical yield > 30% (with respect to [14C]‐thiourea) for further evaluations of environmental fate of 6 , in soils and plants. Copyright © 2006 John Wiley & Sons, Ltd. 相似文献
69.
目的探讨谷氨酸是否能够影响腺苷A2A受体对一氧化氮合酶(NOS)活力的调节。方法用1000ng/ml脂多糖(LPS)刺激小胶质细胞,分别加入100nmol/L A2A受体激动剂CGS21680以及不同浓度的谷氨酸(0,1,0,25,0,5mmol/L)干预,观察NOS活力变化。结果LPS诱导NOS活力增高,激活A2A受体可以产生抑制作用;0,25及0.5mmoL/L谷氨酸和A2A受体激动剂同时存在时,NOS活力进一步增高。结论高浓度谷氨酸可逆转腺苷A2A受体激动剂抑制升高NOS活力的作用。 相似文献
70.